Among 6 analysts covering Celator Pharma (NASDAQ:CPXX), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Celator Pharma had 8 analyst reports since July 27, 2015 according to SRatingsIntel. Roth Capital maintained the shares of CPXX in report on Tuesday, March 15 with “Buy” rating. On Wednesday, June 1 the stock rating was downgraded by Stifel Nicolaus to “Hold”. The stock of Celator Pharmaceuticals Inc (NASDAQ:CPXX) earned “Neutral” rating by Roth Capital on Tuesday, May 31. The stock of Celator Pharmaceuticals Inc (NASDAQ:CPXX) earned “Hold” rating by Needham on Wednesday, June 1. The rating was maintained by TH Capital on Monday, July 27 with “Buy”. The stock of Celator Pharmaceuticals Inc (NASDAQ:CPXX) has “Buy” rating given on Tuesday, March 15 by H.C. Wainwright. Needham initiated Celator Pharmaceuticals Inc (NASDAQ:CPXX) on Tuesday, April 12 with “Buy” rating. The firm has “Buy” rating given on Tuesday, March 15 by Janney Capital. See Celator Pharmaceuticals Inc (NASDAQ:CPXX) latest ratings:
The stock of Codexis, Inc. (NASDAQ:CDXS) is a huge mover today! About 75,999 shares traded. Codexis, Inc. (NASDAQ:CDXS) has risen 9.52% since August 15, 2016 and is uptrending. It has outperformed by 2.50% the S&P500.The move comes after 7 months negative chart setup for the $178.52M company. It was reported on Mar, 22 by Barchart.com. We have $4.08 PT which if reached, will make NASDAQ:CDXS worth $14.28M less.
Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The company has market cap of $1.28 billion. The Firm is engaged in developing products to improve patient outcomes in cancer. It currently has negative earnings. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.
It closed at $30.24 lastly. It is down 6.00% since February 20, 2017 and is uptrending. It has underperformed by 1.03% the S&P500.
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The company has market cap of $178.52 million. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing clients to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. It currently has negative earnings. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients and Codex Biocatalyst Panels and Kits.
Investors sentiment decreased to 1.13 in Q4 2016. Its down 0.63, from 1.76 in 2016Q3. It is negative, as 5 investors sold Codexis, Inc. shares while 18 reduced holdings. 6 funds opened positions while 20 raised stakes. 16.86 million shares or 3.85% less from 17.53 million shares in 2016Q3 were reported. Legal General Grp Inc Public Limited Company reported 11,199 shares. Blackrock Advsr Llc holds 0% in Codexis, Inc. (NASDAQ:CDXS) or 12,249 shares. Nantahala Capital Mngmt Ltd Limited Liability Company holds 2.68% or 5.60M shares. Geode Capital Management Ltd Llc holds 0% in Codexis, Inc. (NASDAQ:CDXS) or 217,453 shares. Barclays Public Ltd Liability Company holds 0% or 562 shares in its portfolio. State Board Of Administration Of Florida Retirement invested 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Bridgeway Cap Management Inc owns 266,000 shares. Baillie Gifford holds 0.01% or 1.19M shares in its portfolio. New York-based Tower Research Limited Liability Co (Trc) has invested 0% in Codexis, Inc. (NASDAQ:CDXS). Dimensional Fund Limited Partnership holds 0% or 25,879 shares. Prescott Group Incorporated Mngmt Ltd Limited Liability Company has 288,275 shares. Spark Investment Management holds 0.06% or 151,200 shares in its portfolio. Citigroup has invested 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Schwab Charles Investment Mngmt holds 0% or 55,370 shares. Goldman Sachs Gru invested in 18,576 shares or 0% of the stock.
Since November 15, 2016, it had 1 insider purchase, and 0 selling transactions for $48,300 activity. $48,300 worth of Codexis, Inc. (NASDAQ:CDXS) was bought by Yang Patrick Y.
Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on May, 8. They expect $-0.11 EPS, up 26.67% or $0.04 from last year’s $-0.15 per share. After $-0.12 actual EPS reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -8.33% EPS growth.
Among 3 analysts covering Codexis (NASDAQ:CDXS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Codexis had 5 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, January 4 by Ladenburg Thalmann. The stock of Codexis, Inc. (NASDAQ:CDXS) earned “Equal-Weight” rating by First Analysis on Thursday, January 26. Zacks upgraded the shares of CDXS in report on Wednesday, August 26 to “Hold” rating. As per Wednesday, August 12, the company rating was downgraded by Zacks. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, January 6.
